We are always evolving in an ever-changing industry.

Keep up-to-date with PrECOG by visiting our news page regularly.

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

Trial PrE0405 met its primary endpoint. Venetoclax combined with bendamustine+rituximab as the first therapy for MCL in patients over age 60 led to a complete response rate of 85%. The American Society of Hematology 2023 annual meeting featured the data. The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate […]

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition, occurring in San Diego, California and virtually December 9 – 12, 2023. The presentations focus on treatments for acute leukemias and lymphoma. Among the data are […]

PrE0404 – Active

Now Open to Enrollment: PrE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NCT03323151

PrE0403 – Active

Now Open to Enrollment: PrE0403 Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy. NCT03113422